ATE470672T1 - Verwendung von cupredoxin-proteine für krebstherapie - Google Patents

Verwendung von cupredoxin-proteine für krebstherapie

Info

Publication number
ATE470672T1
ATE470672T1 AT04780764T AT04780764T ATE470672T1 AT E470672 T1 ATE470672 T1 AT E470672T1 AT 04780764 T AT04780764 T AT 04780764T AT 04780764 T AT04780764 T AT 04780764T AT E470672 T1 ATE470672 T1 AT E470672T1
Authority
AT
Austria
Prior art keywords
cancer therapy
cupredoxin
proteins
cupredoxin proteins
cancer
Prior art date
Application number
AT04780764T
Other languages
English (en)
Inventor
Amanda Chakrabarty
Gupta Tapas Das
Vasu Punj
Olga Zaborina
Yoshinori Hiraoka
Tohru Yamada
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Application granted granted Critical
Publication of ATE470672T1 publication Critical patent/ATE470672T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/80—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/415—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04780764T 2003-08-15 2004-08-10 Verwendung von cupredoxin-proteine für krebstherapie ATE470672T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41455003P 2003-08-15 2003-08-15
US10/720,603 US7491394B2 (en) 2001-02-15 2003-11-24 Cytotoxic factors for modulating cell death
PCT/US2004/025982 WO2005018662A1 (en) 2003-08-15 2004-08-10 Use of polypeptides of the cupredoxin family in cancer therapy

Publications (1)

Publication Number Publication Date
ATE470672T1 true ATE470672T1 (de) 2010-06-15

Family

ID=34221130

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04780764T ATE470672T1 (de) 2003-08-15 2004-08-10 Verwendung von cupredoxin-proteine für krebstherapie

Country Status (19)

Country Link
US (4) US7491394B2 (de)
EP (2) EP2263682A1 (de)
JP (1) JP2007502818A (de)
KR (1) KR20060098358A (de)
AP (1) AP2006003537A0 (de)
AT (1) ATE470672T1 (de)
AU (1) AU2004266632A1 (de)
BR (1) BRPI0413574A (de)
CA (1) CA2535581A1 (de)
DE (1) DE602004027637D1 (de)
EA (1) EA009897B1 (de)
EC (1) ECSP066422A (de)
GE (1) GEP20105022B (de)
IL (1) IL173576A0 (de)
NO (1) NO20061168L (de)
NZ (1) NZ545355A (de)
OA (1) OA13308A (de)
TN (1) TNSN06059A1 (de)
WO (1) WO2005018662A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096663B2 (en) * 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US7338766B2 (en) 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US7618939B2 (en) 2001-02-15 2009-11-17 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
EP1797114A4 (de) 2004-10-07 2009-07-15 Ananda Chakrabarty Aus cupredoxin abgeleitete transportmittel und verfahren zu ihrer verwendung
US9434770B2 (en) * 2004-10-07 2016-09-06 Tapas K Das Gupta Modified cupredoxin derived peptides
US9968685B2 (en) 2004-10-07 2018-05-15 Brad N. Taylor Methods to treat cancer with cupredoxins
WO2006127477A2 (en) * 2005-05-20 2006-11-30 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
AU2006251644A1 (en) * 2005-05-20 2006-11-30 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
EP1888106A4 (de) * 2005-05-20 2009-01-14 Univ Illinois Zusammensetzungen und verfahren zur behandlung von ephrinsignalisierung mit cupredoxinen
CA2615560A1 (en) * 2005-07-19 2007-03-01 The Board Of Trustees Of The University Of Illinois Compositions and methods to control angiogenesis with cupredoxins
JP2009502135A (ja) * 2005-07-19 2009-01-29 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 血液脳関門を越えるための、および脳癌細胞内への輸送因子、並びにその使用方法
US10266868B2 (en) 2006-05-19 2019-04-23 The Board Of Trustees Of The University Of Illinois Compositions for treating HIV infection with cupredoxin and cytochrome C
JP2010502765A (ja) 2006-09-11 2010-01-28 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ キュプレドキシン由来ペプチドの修飾及びそれを使用する方法
AU2007296429A1 (en) * 2006-09-14 2008-03-20 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
RU2009125599A (ru) 2006-12-04 2011-01-20 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс (Us) Композиции и способы лечения рака cpg-богатой днк и купредоксинами
WO2008086523A2 (en) * 2007-01-11 2008-07-17 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
KR20090114414A (ko) * 2007-02-08 2009-11-03 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 쿠프레독신으로 암을 예방하는 조성물과 방법
PT2340021E (pt) * 2008-09-18 2013-01-25 Hoffmann La Roche Pirrolidino-2-carboxamidas substituídas
ES2786253T3 (es) 2013-03-14 2020-10-09 Immusoft Corp Métodos para la diferenciación y transducción in vitro de células b de memoria con vectores virales pseudotipados vsv-g
PL3234107T3 (pl) 2014-12-19 2023-01-16 Immusoft Corporation Limfocyty b do dostarczania in vivo środków terapeutycznych
WO2016176573A1 (en) * 2015-04-30 2016-11-03 Board Of Regents, The University Of Texas System Antibacterial polypeptide libraries and methods for screening the same
CN111705026B (zh) * 2020-06-02 2021-11-26 华中农业大学 一种牛支原体Mbov_0280基因突变株及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4585644A (en) 1984-06-04 1986-04-29 Phillips Petroleum Company Changing oil tubes in a carbon black reactor
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5827934A (en) * 1988-03-08 1998-10-27 The University Of Wyoming Cytotoxic diphtheria toxin fragments
DE69034078T2 (de) 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5407683A (en) * 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
PT584348E (pt) 1992-03-11 2005-10-31 Powderject Vaccines Inc Vacina genetica para virus da imunodeficiencia
EP0646178A1 (de) 1992-06-04 1995-04-05 The Regents Of The University Of California Expression kassette mit im säugetier wirt funktionnellen regulator sequenzen
US5928647A (en) 1993-01-11 1999-07-27 Dana-Farber Cancer Institute Inducing cytotoxic T lymphocyte responses
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5972899A (en) * 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
AU2002311753B2 (en) 2001-02-15 2008-04-03 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7338766B2 (en) 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
US7301010B2 (en) 2001-02-15 2007-11-27 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
UA88272C2 (ru) 2003-08-15 2009-10-12 Борд Оф Трастиз Оф Зе Юниверсити Оф Иллинойс Применение полипептидов семейства купредоксина в лечении рака
EP1797114A4 (de) 2004-10-07 2009-07-15 Ananda Chakrabarty Aus cupredoxin abgeleitete transportmittel und verfahren zu ihrer verwendung
WO2006127477A2 (en) 2005-05-20 2006-11-30 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
AU2006251644A1 (en) 2005-05-20 2006-11-30 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
JP2009502135A (ja) 2005-07-19 2009-01-29 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 血液脳関門を越えるための、および脳癌細胞内への輸送因子、並びにその使用方法

Also Published As

Publication number Publication date
IL173576A0 (en) 2006-07-05
AU2004266632A1 (en) 2005-03-03
AP2006003537A0 (en) 2006-04-30
OA13308A (en) 2007-04-13
EP2263682A1 (de) 2010-12-22
DE602004027637D1 (de) 2010-07-22
US7888468B2 (en) 2011-02-15
WO2005018662A1 (en) 2005-03-03
BRPI0413574A (pt) 2006-10-17
JP2007502818A (ja) 2007-02-15
US10421801B2 (en) 2019-09-24
CA2535581A1 (en) 2005-03-03
US20140179617A1 (en) 2014-06-26
EP1653990B1 (de) 2010-06-09
US20060040269A1 (en) 2006-02-23
NO20061168L (no) 2006-05-15
EA200600424A1 (ru) 2006-08-25
EP1653990A1 (de) 2006-05-10
TNSN06059A1 (en) 2007-10-03
US20060292136A1 (en) 2006-12-28
EA009897B1 (ru) 2008-04-28
ECSP066422A (es) 2006-11-24
KR20060098358A (ko) 2006-09-18
US7491394B2 (en) 2009-02-17
GEP20105022B (en) 2010-06-25
NZ545355A (en) 2009-10-30
US20080182782A1 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
ATE470672T1 (de) Verwendung von cupredoxin-proteine für krebstherapie
CY2016035I2 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
DE60315135D1 (de) Therapiesonde
ATE465180T1 (de) Therapeutische anti-igfr1-antikörper- kombinationen
IL181779A (en) A group of protein-based medical molecules
EE200500035A (et) Personaalne teraapiasektsioon
DK1755671T3 (da) Terapi af platinresistent cancer
DE60321130D1 (de) Variation von parametern zur neurostimulation
DE502005006470D1 (de) Verwendung von sulfonylharnstoffen
IS8397A (is) Meðferðarfræðilegar bindisameindir
ATA19522003A (de) Gag-bindungsproteine
DE502004011575D1 (de) Verwendung von Dioldimerfettsäureestern
ATE417842T1 (de) Verwendung von trisubstituierten benzopyranonen
DE60207053D1 (de) Rekombinante gelatineartige proteine zur verwendung als plasmaexpander
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE602005001066D1 (de) Komplexe Emulsionen von Perfluoropolyethern
DE602004004262D1 (de) Ultraschallbehandlung von gewebematrices
ATE457168T1 (de) Transdermales therapeutisches system von gestoden
DE50311406D1 (de) Verwendung von Formkörpern
DE602004026773D1 (de) Verfahrensherstellung von ethern
ATE455770T1 (de) N-alkynyl-2-heteroaryloxyalkylamide zur verwendung als fungizide
DE50308460D1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen
DE502004002460D1 (de) Verwendung von copolymerisaten als hilfsmittel für die lederherstellung
DE60328516D1 (de) Thia-epothilon derivate zur krebsbehandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties